Bringing Cure...Building Hope...
Home | Blog | Events
Pharma legitimate consultant and facilitator in Delhi India

KYMRIAH (tisagenlecleucel) suspension for intravenous infusion
Initial U.S. Approval: 2017 Available in India.

KYMRIAH is used to Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in adults whose cancer has come back or did not respond after two or more previous treatments. Kymriah is a type of advanced therapy medicine called a 'gene therapy product'. Brand KYMRIAH (tisagenlecleucel) suspension can be imported for personal use under "patient name basis" treatment in India. For this applicant is required to make an request application with required document. IPN, New Delhi will do the necessary process to obtain permission from Drugs Controller General (India) to import.

Generic Name: tisagenlecleucel Brand Name: KYMRIAH
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in adults whose cancer has come back or did not respond after two or more previous treatments. Kymriah is a type of advanced therapy medicine called a 'gene therapy product'. .

Therapeutic indications and Usage KYMRIAH is a CD19-directed genetically modified autologous T-cell immunotherapy indicated for the treatment of:
• Patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
• Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
Limitations of Use: KYMRIAH is not indicated for treatment of patients with primary central nervous system lymphoma.
• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response.
If you have any questions about your illness, talk to your doctor
Source Details: Patient Information

Patient Name Basis Treatment IPN, New Delhi can facilitate patient to import of "KYMRIAH (tisagenlecleucel) suspension" in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Healthcare Professional In India If you have any question, please email IPN Support Team or Call Indian Pharma Network for KYMRIAH (tisagenlecleucel) suspension price list or cost in India. on
Mr. Tarun:- +91 9891 296 838
Mr. Neeraj:- +91 9811 747 774

Indian Pharma Network, New Delhi. India

IPN, Delhi are legitimate consultant and facilitator in India, group of highly qualified pharma professionals.
Specialized in Oncology and other pharma products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Mumbai | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur | Punjab | Chandigarh
Our Overseas Network Uk | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Saudi Arabia | South Africa

KYMRIAH (tisagenlecleucel) suspensioninjection
Note:-

We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.

Facts of KYMRIAH (tisagenlecleucel) suspension

Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer (adoptive cell transfer).

Source content : www.accessdata.fda.gov

IPN, New Delhi can facilitate patient to import of "KYMRIAH (tisagenlecleucel) suspension" in small quantities for personal use. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. with over 20 years of domain experience.

For procurement cost of KYMRIAH (tisagenlecleucel) suspension in India, Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the KYMRIAH (tisagenlecleucel) suspension medicine cost price in India.

The order for KYMRIAH (tisagenlecleucel) suspension will be confirmed only after
1. submitting Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).
2. Permission from obtained from the office of the Drugs Controller General (India).
3. Availability of KYMRIAH (tisagenlecleucel) suspension from authorised distributor.

Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) in adults whose cancer has come back or did not respond after two or more previous treatments. Kymriah is a type of advanced therapy medicine called a 'gene therapy product'. This is a type of medicine that works by delivering genes into the body.
Tisagenlecleucel is indicated for the treatment of those under 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse; or adults with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma. In May 2022, the indication in the US was updated to include the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

KYMRIAH (tisagenlecleucel) suspension, for intravenous use Initial U.S. Approval: 2019

Capsules: 100 mg.

For KYMRIAH (tisagenlecleucel) suspensionIndications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma For More Details

Novartis' Kymriah bags FDA nod to face off against Gilead's Yescarta in follicular lymphoma For More Details

FDA Approvals Roundup: Evrysdi, Kymriah, Tibsovo For More Details

Step 1. Send a request for your medicine online:- Applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP).

Step 2. Verification of documents:- We verify your a prescription and necessary documents to import drugs in small quantities for personal use.

Step 3. Permission to Import:- After getting approval of Drugs Controller General (India), we start the process to import of drugs as mentioned in prescription for personal use.

Step 4. We source your medicine:- Our expert sourcing team work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 5. Delivery of medicine:- After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Doctor’s Prescription –
We would require prescription from Registered Medical Practitioner (RMP) stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process.

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find out -
KYMRIAH (tisagenlecleucel) suspension price in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
KYMRIAH (tisagenlecleucel) suspension price in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
KYMRIAH (tisagenlecleucel) suspension price in North America – Mexico.
KYMRIAH (tisagenlecleucel) suspension price in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
KYMRIAH (tisagenlecleucel) suspension price in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
KYMRIAH (tisagenlecleucel) suspension price in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
KYMRIAH (tisagenlecleucel) suspension price in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
KYMRIAH (tisagenlecleucel) suspension price in Australia and New Zealand.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

Get Access To KYMRIAH (tisagenlecleucel) suspension In India

Indian Pharma Network (IPN), Delhi India is a leading Pharmaceutical Distributor / Supplier / Exporter / Importer of Anti-Cancer Medicines, used in leukemia treatment. Brand Name "KYMRIAH (tisagenlecleucel) suspension" or Generic Name "tisagenlecleucel capsules" can be imported for personal use under "patient name basis" treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at urgent@indianpharmanetwork.co.in or call/WhatsApp at +91 9891296838 / 9811747774 to get access as per norms.